Biology of cancer development in the GI tract
|
|
- Hector Neal
- 5 years ago
- Views:
Transcription
1 1 Genesis and progression of GI cancer a genetic disease Colorectal cancer Fearon and Vogelstein proposed a genetic model to explain the stepwise formation of colorectal cancer (CRC) from normal colonic tissues. The model states: (1) CRC results from mutations in genes with important functions in regulating cell proliferation or DNA repair, (2) mutations in >1 gene are required, and (3) the sequence of mutations is important in determining the formation of CRC. Normal mucosa Characteristics of the two major pathways in CRC Chromosomal instability pathway Genetic alterations through chromosomal losses and gains Deletion 1p Deletion 8p LOH 17p LOH 18q APC COX2 K-ras DCC/Smad4 p53 Early adenoma???? Intermediate adenoma Late adenoma Carcinoma???? Metastasis These altered genes can be divided into two classes: tumour suppressors that either inhibit cell proliferation or promote apoptosis, and oncogenes that promote cell proliferation and tumour progression. β-catenin BAX TCF-4 IGF-IIR TGF-βRII MLH1 MSH2 MSH6 Epigenetics CIMP hypermethylation Microsatellite instability pathway Genetic alterations through defective DNA mismatch repair proteins CRC, Colorectal cancer. Phylogenetically, CRCs can be divided into two molecular subtypes: those with chromosomal instability (CIN) and those with microsatellite instability (MSI). Carcinomas with MSI present cancerinitiating mutations that inactivate the function of mismatch repair (MMR) genes (e.g. MSH2, MSH6, MLH1 and PMS2) leading to hypermutated genomes. This is known as the mutator phenotype. MSI tumours frequently present a CpG island methylator phenotype (CIMP) leading to the repression of tumour suppressor genes including MLH1. 1. Is MSI always related to hereditary colon cancer? 2. Can you comment on potential therapies for hypermutated colon cancer? 3. Can you mention three genes involved in the chromosomal instability pathway? 1 Palmer
2 Genesis and progression of GI cancer a genetic disease (continued) Gastric cancer The vast majority of gastric cancers are adenocarcinomas, which can be further subdivided into intestinal and diffuse types according to the Lauren classification. Most gastric cancers are associated with infectious agents, including the bacterium Helicobacter pylori and Epstein Barr virus (EBV). A minority are associated with germline mutation in E-cadherin (CDH1) or MMR genes, whereas sporadic MMR-deficient gastric cancers have epigenetic silencing of MLH1 in the context of CIMP. Gene expression or DNA sequencing have been used in molecular profiling of gastric cancer, but have not led to a clear biological classification scheme. More recent studies by The Cancer Genome Atlas (TCGA) have permitted more precise molecular classification of gastric cancer by identifying dysregulated pathways and candidate drivers of distinct classes. Diffuse type MSI-H (-6%) MSI-H (13-2%) E-cadherin mutation (41-5%) p53 mutation (-33%) CD44 aberrant transcript Cyclin E overexpression (1%) CDC25B overexpression N-cadherin overexpression (43%) Twist 1 overexpression (39%) K-sam amplification (33%) c-met amplification (39%) Reduced nm23 (<52%) Genetic alterations in gastric cancer Normal gastric mucosa Early cancer Carcinoma Metastasis Metaplasia (Adenoma) Intestinal type Telomerase activation/ TERT expression p53 mutation (25-63%) K-ras mutation (1%) Reduced p27 expression APC mutation (4-6%) Bcl-2 loss (43%) c-met amplification (19%) Cyclin E overexpression (14-2%) 18q (DCC) loss (5%) β-catenin mutation (27%) c-erbb2 amplification (2%) CD44 aberrant transcript E-cadherin reduction (6%) SIP1 overexpression (55%) Reduced nm23 (52%) Pancreatic cancer Normal tissue Lumen of duct Duct epithelium Submucosa Normal PanIN-1A PanIN-1B PanIN-2 PanIN-3 Overexpression of Her-2/neu Point mutations of K-ras Inactivation of p16 Cancerous tissue Inactivation of p53, DPC4 and BRCA2 The genetic progression of pancreatic carcinoma Published in Expert Reviews in Molecular Medicine by Cambridge University Press (21) Pancreatic adenocarcinoma presents a progression from distinct types of precursor lesions, a propensity for both local invasion and distant metastasis, an extensive stromal reaction (desmoplasia) resulting in a hypovascular and hypoxic microenvironment, reprogramming of cellular metabolism, and evasion of tumour immunity. There is a stepwise progression of pancreatic intraepithelial neoplasia (PanIN) from low grade to high grade in types 1, 2 and 3. These types are associated with accumulating genetic alterations. More than 9% of cases of PanIN of all grades have KRAS mutations. Mutational inactivation of the CDKN2A, p53 and SMAD4 tumour suppressors occurs later in type 2 and type 3 lesions of PanIN. In addition, 8% have activating mutations in GNAS and more than 5% have inactivation of RNF43 (an antagonist of Wnt signalling). The pancreatic adenocarcinoma genome is also characterised by diverse, large-scale chromosomal changes with frequent amplifications, deletions and rearrangements. 1. Are there any gastric cancers with MSI? 2. How are diffuse type gastric carcinomas molecularly defined? 3. What is the most common molecular alteration in pancreatic carcinomas? 2
3 New molecular characterisation of GI tumours Colorectal cancer Recent studies by TCGA show that nonhypermutated CRC tumours, irrespective of anatomical origin, present equivalent types of copy number, expression profile, DNA methylation and microrna (mirna) changes. Over 9 had a mutation in one or more members of the Wnt signalling pathway, dominantly in APC. However, there were some differences between tumours from the right colon and all other sites. Hypermethylation was more common in the right colon, and three-quarters of hypermutated samples came from the same site, although not all had MSI. Mutation rate (mutations per 1 6 bases) MLH1 MLH3 MSH2 MSH3 MSH6 PMS2 POLE Epigenetic silencing Non-silent Silent.1 Hypermutated Non-hypermutated Tumour site MSI status CIMP status MLH1 silencing Frameshift mutation Missense/nonsense mutation Mutation frequency (%) Mutation frequency (%) % 81% Hypermutated tumours 51% 51% 46% 31% 31% 26% 26% 6% 43% Non-hypermutated tumours 31% ACVR2A APC TGFBR2 BRAF MSH3 MSH6 MYO1B TCF7L2 CASP8 CDC27 FZD3 MIER3 TCERG1 MAP7 PTPN12 18% 11% 1% 9% 9% 7% 6% 5% 3% APC TP53 KRAS TTN PIK3CA FBXW7 SMAD4 NRAS TCF7L2 FAM123B SMAD2 CTNNB1 KIAA184 SOX9 ACVR1B GPC6 EDNRB 93% of non-hypermutated and 97% of hypermutated cases had a deregulated Wnt signalling pathway. New findings included recurrent mutations in FAM123B, ARID1A and SOX9 and very high levels of overexpression of the Wnt ligand receptor gene FZD1. Activation of Wnt signalling and inactivation of the TGF-β signalling pathway result in activation of MYC. Mutational and integrative analyses emphasise the critical role of MYC in CRC. Integrated analysis revealed a diverse set of changes in TCF/LEF-encoding genes, suggesting additional roles for TCF/LEF factors. Mutations in the ubiquitin ligases RNF43 and ZNRF3 or fusions of RSPO2/3 genes are alterations that activate Wnt/beta-catenin oncogenic signalling and represent a promising level for drug intervention. 1. Which oncogenic pathway is the most frequently altered by mutations in CRC? 2. Is the TGF-β pathway activated or inactivated by mutations in CRC? 3. Which genes present fusions that activate oncogenic Wnt signalling? 3 Palmer
4 New molecular characterisation of GI tumours (continued) Gastric cancer Recent studies by TCGA propose a molecular classification dividing gastric cancer into four subtypes: 1. Tumours positive for EBV, which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, CD274 (also known as PD-L1) and DCD1LG2 (also known as PD-L2). Subtype Tumour purity TP53 mut. SCNA high Diffuse MLH1 silencing MSI high CDKN2A silencing PIK3CA mut. EBV positive 1 5 Mutations per Mb Copy number Chr 1 Chr 22 EBV MSI GS CIN Tumour purity Not available Molecular/clinical features Yes No Not available Gain Loss DNA methylation mrna microrna Protein EBV positive EBV (EBV-CIMP) 64 MSI (hypermutated) MSI high GS (Genomically stable) 25 SCNA high cluster 147 CIN (chrom. instability) 227 tumours 2. Microsatellite unstable tumours, which show elevated mutation rates, including mutations of genes encoding targetable oncogenic signalling proteins. 3. Genomically stable tumours, which are enriched for the diffuse histological variant and mutations of RHOA or fusions involving RHO-family GTPase-activating proteins Tumours with CIN, which show marked aneuploidy and focal amplification of receptor tyrosine kinases. Identification of these subtypes provides a roadmap for patient stratification and trials of targeted therapies. Lauren classification diffuse (%) Males (%) EBV MSI GS CIN Age at initial diagnosis Number of samples GE junction cardia Fundus body Antrum pylorus EBV MSI GS CIN EBV MSI GS CIN 1. Do chromosome instability and mutations in tyrosine kinase receptors frequently co-occur in gastric cancer? 2. Are mutations in the PIK3CA gene frequent in microsatellite unstable gastric tumours? 3. With which molecular subtype of gastric cancer is a diffuse histology related? 4
5 New molecular characterisation of GI tumours (continued) Pancreatic cancer Somatic mutations in ataxia telangiectasia mutated (ATM) are present in significant proportions of patients (8%), highlighting the importance of BRCA-mediated DNA damage repair mechanisms in sporadic pancreatic ductal adenocarcinoma (PDAC) as well as familial disease. Mutations in genes involved in chromatin remodelling such as ARID1A, EPC1 and ARID2 are frequently observed, indicating chromatin remodelling may have an important role in PDAC. Novel mutations in genes traditionally described for their roles in axon guidance have been observed by a combination of genomic data and supportive experimental evidence from independent murine Sleeping Beauty (SB) mutagenesis screens. Axon guidance is integral to organogenesis, regeneration, wound healing and other basic cellular processes. The widespread genomic aberrations observed in axon guidance genes suggest they may have a role in PDAC. This observation joins mounting evidence in other cancer, including a recent report demonstrating ROBO2 mutations in liver fluke-associated cholangiocarcinoma. CNV, Copy number variation; IPMN, intraductal papillary mucinous neoplasm; LOH, loss of heterozygosity; PDAC, pancreatic ductal adenocarcinoma. 1. Which genes involved in chromatin remodelling are significantly mutated in pancreatic cancer? 2. Is BRCA-dependent DNA repair a cellular function altered by mutations in pancreatic cancer? 3. Are genes involved in axon guidance altered in pancreatic cancer? 5 Palmer
6 Summary: CRC progression is the consequence of a stepwise accumulation of mutations in tumour suppressor genes and oncogenes, the most frequent alteration observed being activation of the Wnt/beta-catenin pathway Both CRC and gastric cancer present a major group of non-hypermutated tumours and a minor population of hypermutated/msi tumours Pancreatic cancer progressively accumulates mutations in KRAS, CDKN2A, p53 and SMAD4, but also presents alterations in genes involved in chromatin remodelling and axon guidance Further Reading Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 212; 491: Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 212; 487: Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 214; 513: Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 199; 61: Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet 214; 46: Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature 212; 488:
Development of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationPancreatic intraepithelial
Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial
More informationThe mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationThe silence of the genes: clinical applications of (colorectal) cancer epigenetics
The silence of the genes: clinical applications of (colorectal) cancer epigenetics Manon van Engeland, PhD Dept. of Pathology GROW - School for Oncology & Developmental Biology Maastricht University Medical
More informationLa genetica del carcinoma colo-rettale
La genetica del carcinoma colo-rettale Ivana Cataldo Ospedale Ca Foncello, Treviso ARC-NET Centro di Ricerca Applicata sul Cancro AOUI, Verona OUTLINE What s new in colorectal cancer? Pathological Markers
More informationGENOMICS OF PANCREATIC TUMOURS
GENOMICS OF PANCREATIC TUMOURS - WHAT WE NOW KNOW Ann-Marie Patch, 1 Andrew Barbour, 2,3 Nicola Waddell 1,4 1. QIMR Berghofer Medical Research Institute, Herston, Brisbane, Queensland, Australia. 2. Surgical
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationPresent State of Gene Diagnosis and Future Prospects
Clinical Medicine: Cancer Present State of Gene Diagnosis and Future Prospects JMAJ 45(3): 118 124, 2002 Eiichi TAHARA Chairman, Hiroshima Cancer Seminar Foundation Abstract: The entire base sequence of
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationGenomic Instability. Kent Nastiuk, PhD Dept. Cancer Genetics Roswell Park Cancer Institute. RPN-530 Oncology for Scientist-I October 18, 2016
Genomic Instability Kent Nastiuk, PhD Dept. Cancer Genetics Roswell Park Cancer Institute RPN-530 Oncology for Scientist-I October 18, 2016 Previous lecturers supplying slides/notes/inspiration Daniel
More informationMolecular Subtyping of Endometrial Cancer: A ProMisE ing Change
Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change Charles Matthew Quick, M.D. Associate Professor of Pathology Director of Gynecologic Pathology University of Arkansas for Medical Sciences
More informationClonal evolution of human cancers
Clonal evolution of human cancers -Pathology-based microdissection and genetic analysis precisely demonstrates molecular evolution of neoplastic clones- Hiroaki Fujii, MD Ageo Medical Laboratories, Yashio
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationComparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Article Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas Graphical Abstract Authors Yang Liu, Nilay S. Sethi, Toshinori Hinoue,..., Vésteinn Thorsson, Adam J. Bass, Peter W. Laird Correspondence
More informationoncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
More informationIntegration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium
Integration of Cancer Genome into GECCO- Genetics and Epidemiology of Colorectal Cancer Consortium Ulrike Peters Fred Hutchinson Cancer Research Center University of Washington U01-CA137088-05, PI: Peters
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationCancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
More informationColorectal cancer molecular biology moves into clinical practice
1 Department of Laboratory Medicine, University of Washington, Washington, USA 2 Clinical Research Division, Fred Hutchison Cancer Research Center, Washington, USA 3 Department of Medicine, University
More informationNeoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath
Neoplasia 18 lecture 6 Dr Heyam Awad MD, FRCPath ILOS 1. understand the role of TGF beta, contact inhibition and APC in tumorigenesis. 2. implement the above knowledge in understanding histopathology reports.
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationMarcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationDisclosures 9/25/2012. Emerging Biomarkers for Risk Stratification, Prognosis and Prediction of Treatment Responses in Colorectal Carcinoma (CRC)
Emerging Biomarkers for Risk Stratification, Prognosis and Prediction of Treatment Responses in Colorectal Carcinoma (CRC) Disclosures 21 st ANNUAL SYMPOSIUM ON MOLECULAR PATHOLOGY Clinical Applications
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationKaryotype analysis reveals transloction of chromosome 22 to 9 in CML chronic myelogenous leukemia has fusion protein Bcr-Abl
Chapt. 18 Cancer Molecular Biology of Cancer Student Learning Outcomes: Describe cancer diseases in which cells no longer respond Describe how cancers come from genomic mutations (inherited or somatic)
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationUniversity of Louisville
GRAND ROUND PRESENTATION 01-13-05 DIPENDRA PARAJULI Carcinogenesis: Its Correlation in Gastrointestinal Cancers In adult humans cell are continuously lost Cells division = Cell loss -two trillion cell
More informationMohammed El-Khateeb. Tumor Genetics. MGL-12 May 13 th Chapter 22 slide 1 台大農藝系遺傳學
Mohammed El-Khateeb Tumor Genetics MGL-12 May 13 th 2014 台大農藝系遺傳學 601 20000 Chapter 22 slide 1 Cancer Genetics Types of Genetic Alterations in Cancer Evidence that Mutations Cause Cancer Multistage Model
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationEpstein-Barr virus driven promoter hypermethylated genes in gastric cancer
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epstein-Barr virus driven promoter hypermethylated genes in gastric cancer J Yu *, KF To, QY Liang K e y M e s s a g e s 1. Somatostatin receptor 1
More informationNature Medicine: doi: /nm.3967
Supplementary Figure 1. Network clustering. (a) Clustering performance as a function of inflation factor. The grey curve shows the median weighted Silhouette widths for varying inflation factors (f [1.6,
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationMolecular Cell Biology. Prof. D. Karunagaran. Department of Biotechnology. Indian Institute of Technology Madras
Molecular Cell Biology Prof. D. Karunagaran Department of Biotechnology Indian Institute of Technology Madras Module 9 Molecular Basis of Cancer, Oncogenes and Tumor Suppressor Genes Lecture 2 Genes Associated
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationEmerging" hallmarks of cancer, a. Reprogramming of energy metabolism b. Evasion of the immune system, Enabling characteristics, a.
HALLMARKS OF CANCER - Together dictate the malignant phenotype. 1. Self-sufficiency in growth signals 2. Insensitivity to growth inhibitory signals 3. Evasion of cell death 4. Limitless replicative potential
More informationMolecular Pathology of Gastric Cancer
Molecular Pathology of Gastric Cancer Novel insights and possible future applications Fátima Carneiro i3s/ipatimup& Medical Faculty/ CHS João Porto, Portugal Outline 1. Major histological types of gastric
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationClinical, Pathologic and Molecular Updates
Colorectal Cancer: Clinical, Pathologic and Molecular Updates Joanna A. Gibson, M.D./Ph.D. Yale University School of Medicine/Yale New Haven Hospital, Department of Pathology Gastrointestinal, Pancreaticobiliary
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationSupplementary Figure 1. Estimation of tumour content
Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent
More information1 Molecular Biology of Colon
Chapter 1.qxd 4/3/06 6:39 PM Page 1 1 Molecular Biology of Colon Cancer William M. Grady, MD Summary Colorectal cancer affects approx 140,000 people in the United States each year, resulting in more than
More informationSurveillance of Individuals At High Risk For Developing Pancreatic Cancer
Surveillance of Individuals At High Risk For Developing Pancreatic Cancer Marco Bruno Erasmus Medical Center, Rotterdam Pancreatic Cancer Facts & figures One of the most fatal malignancies Overall 5-year
More informationGenetic Aspects of Inherited colorectal cancer (CRC)
Genetic Aspects of Inherited colorectal cancer (CRC) New data New insights DNA repair Cancer Hub 3/2014 2004 Service for genetics of GI Cancer Oncology Tamar Peretz A. Hubert L. Kadouri N. Halpern M. Plesser
More informationof 20 to 80 and subsequently declines [2].
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationRath, N., and Olson, M. (2016) Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nature Medicine, 22(5), pp. 462-463. There may be differences between this version and the published
More informationMohammed El-Khateeb. Tumor Genetics. MGL-12 July 21 st 2013 台大農藝系遺傳學 Chapter 22 slide 1
Mohammed El-Khateeb Tumor Genetics MGL-12 July 21 st 2013 台大農藝系遺傳學 601 20000 Chapter 22 slide 1 Cellular Basis of Cancer Cancer is a collection of diseases characterized by abnormal and uncontrolled growth
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationMSI positive MSI negative
Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationGenetic Modifiers of Chemotherapy for Colorectal Cancer
Genetic Modifiers of Chemotherapy for Colorectal Cancer September 27, 2011 John M. Carethers, M.D. Professor of Internal Medicine University of Michigan 1,233,700 cases/year Worldwide ~146,000 cases/year
More informationGenetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
More informationCancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation
Cancer The fundamental defect is unregulated cell division. Properties of Cancerous Cells Altered growth and proliferation Loss of growth factor dependence Loss of contact inhibition Immortalization Alterated
More informationmirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download:https://getbooksolutions.com/download/test-bank-for-robbinsand-cotran-pathologic-basis-of-disease-9th-edition-by-kumar Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationCase presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma
Genomic/morphological classification of endometrial carcinoma Robert A. Soslow, MD soslowr@mskcc.org architecture.about.com Case presentation 49 year old woman with vaginal bleeding Underwent endometrial
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More informationComputer Science, Biology, and Biomedical Informatics (CoSBBI) Outline. Molecular Biology of Cancer AND. Goals/Expectations. David Boone 7/1/2015
Goals/Expectations Computer Science, Biology, and Biomedical (CoSBBI) We want to excite you about the world of computer science, biology, and biomedical informatics. Experience what it is like to be a
More informationIdentification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma
Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma Nathaniel L Jones 1, Joanne Xiu 2, Sandeep K. Reddy 2, Ana I. Tergas 1, William
More informationThe use of diagnostic FFPE material in cancer epidemiology research
The use of diagnostic FFPE material in cancer epidemiology research Neil O Callaghan Genetic Epidemiology Laboratory Department of Pathology The University of Melbourne www.pedigree.org.au Overview Who
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/22278 holds various files of this Leiden University dissertation. Author: Cunha Carvalho de Miranda, Noel Filipe da Title: Mismatch repair and MUTYH deficient
More informationDisorders of Cell Growth & Neoplasia. Lecture 4 Molecular basis of cancer
General Pathology VPM 152 Disorders of Cell Growth & Neoplasia Lecture 4 Molecular basis of cancer Enrique Aburto Apr 2010 Skin tumor in a 10-year-old Rottweiler. Considering the external appearance and
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationDetermination Differentiation. determinated precursor specialized cell
Biology of Cancer -Developmental Biology: Determination and Differentiation -Cell Cycle Regulation -Tumor genes: Proto-Oncogenes, Tumor supressor genes -Tumor-Progression -Example for Tumor-Progression:
More informationCancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz
Cancer and Oncogenes Bioscience in the 21 st Century Linda Lowe-Krentz December 1, 2010 Just a Few Numbers Becoming Cancer Genetic Defects Drugs Our friends and family 25 More mutations as 20 you get older
More informationras Multikinase Inhibitor Multikinase Inhibitor 0.1
a ras ** * ** * ** ** ** ** un in et m lu Se ib SL G 32 W 7 So 50 ra 74 fe ni b LY W 294 or 0 tm 02 R an ap n a in Ev my er cin ol im BE us Z2 3 En P 5 za I13 st 0 au rin D as SP ati 60 nib C 012 is 5
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationEpigenetics and Colorectal Cancer Pathogenesis
Cancers 2013, 5, 676-713; doi:10.3390/cancers5020676 Article OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Epigenetics and Colorectal Cancer Pathogenesis Kankana Bardhan and Kebin Liu
More informationUnravelling the Molecular Taxonomies of Gastroesophageal Cancers
Unravelling the Molecular Taxonomies of Gastroesophageal Cancers Patrick Tan, MD PhD Professor, Duke-NUS Medical School Deputy Executive Director, Biomedical Research Council, Agency for Science, Technology
More informationSessile Serrated Polyps
Årsmøtet i Den norske Patologforening 2014 Sessile Serrated Polyps Tor J. Eide Oslo Universitetssykehus The term serrated include a group of lesions with a sawtoothlike appearance of the crypts and the
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationMolecular Diagnosis for Colorectal Cancer Patients
Molecular Diagnosis for Colorectal Cancer Patients Antonia R. Sepulveda MD, PhD, FCAP October, 20, 2010 www.cap.org Welcome to the PHC Webinar Series This talk on The Molecular Diagnosis for Colorectal
More informationGender-related prognostic value and genomic pattern of intra-tumor heterogeneity in colorectal cancer
Carcinogenesis, 2017, Vol. 38, No. 8, 837 846 doi:10.1093/carcin/bgx046 Advance Access publication May 20, 2017 Original Manuscript original manuscript Gender-related prognostic value and genomic pattern
More informationAdenocarcinoma of the pancreas
Adenocarcinoma of the pancreas SEMINARS IN DIAGNOSTIC PATHOLOGY 31 (2014) 443 451 Ralph H.Hruban, MD, David S. Klimstra, MD Paola Parente Anatomia Patologica Casa Sollievo della Sofferenza San Giovanni
More informationTest Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar
Link full download: http://testbankair.com/download/test-bank-for-robbins-cotran-pathologic-basis-of-disease-9th-edition-bykumar-abbas-and-aster Test Bank for Robbins and Cotran Pathologic Basis of Disease
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More information11/18/2015. Gloria Su, Ph.D. Path G4500. Cancer Statistics 2015 (Siegel et al, CA Cancer J CLIN 2015) The Pancreatic Cancer Burden
Mouse Modeling for Human Pancreatic Cancer Gloria Su, Ph.D. gs2157@columbia.edu, ICRC 10-04 Associate Professor Departments of Pathology and Otolaryngology/Head and Neck Surgery Columbia University College
More informationArzu Ensari, MD, PhD Department of Pathology Ankara University Medical School
Precursors of Colorectal Carcinoma Arzu Ensari, MD, PhD Department of Pathology Ankara University Medical School Hyperplastic polyp Adenomatous polyp Colorectal carcinoma IBD-associated (1-2%) Sporadic
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationChapter 2 Molecular Mechanisms of Colorectal Carcinogenesis
Chapter 2 Molecular Mechanisms of Colorectal Carcinogenesis Jatin Roper and Kenneth E. Hung Abstract Colorectal cancer (CRC) presents in three major forms: inherited, sporadic, and familial. Although the
More informationTUMOR-SUPPRESSOR GENES. Molecular Oncology Michael Lea
TUMOR-SUPPRESSOR GENES Molecular Oncology 2011 Michael Lea TUMOR-SUPPRESSOR GENES - Lecture Outline 1. Summary of tumor suppressor genes 2. P53 3. Rb 4. BRCA1 and 2 5. APC and DCC 6. PTEN and PPA2 7. LKB1
More information